Skip Navigation.

Post Award


Patient experiences still undervalued by drug regulators

Published November 14, 2013 by OSP

“Although sponsors bear the financial costs of drug development, patients literally pay with their blood, sweat, and tears. When drugs come before regulators, patients and their family members similarly deserve to be at the heart of the discussion” writes one commentator in support of the FDA’s Patient Focused Drug Development program.

Read More>